scholarly journals Soft Tissue Sarcoma Guidelines

2007 ◽  
Vol 5 (4) ◽  
pp. 364 ◽  
Author(s):  
_ _
Keyword(s):  
United States ◽  
Soft Tissue ◽  
Mortality Rate ◽  
Soft Tissue Sarcoma ◽  
Single Agent ◽  
Soft Tissue Sarcomas ◽  
The United States ◽  
Desmoid Tumors ◽  
Recent Version ◽  
Overall Mortality

Soft tissue sarcomas are the most frequent sarcomas; the annual incidence for 2007 in the United States is estimated at about 9220 cases, with an overall mortality rate of approximately 3560 cases per year. Important updates for the 2007 version of the guidelines include the addition of epirubicin (single agent) and the combination of epirubicin, ifosfamide, and mesna as generally accepted systemic therapy. Imatinib was added as an option for desmoid tumors. For the most recent version of the guidelines, please visit NCCN.org

scholarly journals Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States

Sarcoma ◽  
2018 ◽  
Vol 2018 ◽  
pp. 1-14 ◽  
Author(s):  
Santiago Zuluaga-Sanchez ◽  
Lisa M. Hess ◽  
Sorrel E. Wolowacz ◽  
Yulia D’yachkova ◽  
Emma Hawe ◽  
...  
Keyword(s):  
United States ◽  
Cost Effectiveness ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Meta Analysis ◽  
Single Agent ◽  
Cost Effective ◽  
Standard Of Care ◽  
The United States ◽  
Life Years

Background. Standard first-line treatments for advanced soft tissue sarcoma (STS) have changed little for 40 years, and outcomes have been poor. Recently, the United States (US) Food and Drug Administration conditionally approved olaratumab in combination with doxorubicin (Olara + Dox) based on a randomized phase II trial that reported a significant 11.8-month improvement in median survival versus single-agent doxorubicin (Dox). The present study investigated the cost-effectiveness of Olara + Dox compared with Dox and five other standard-of-care regimens from the US payer perspective. Methods. An economic model was constructed to estimate costs and outcomes over patients’ lifetimes from start of therapy. Progression-free and overall survival were based on survival analysis of patient-level data and a meta-analysis. Adverse-event rates were based on trials. Costs were from published sources. Results. Olara + Dox resulted in an estimated additional 1.27 life-years (LYs) compared with Dox, with an increase in total expected lifetime costs of $133,653. The incremental cost-effectiveness ratio (ICER) was estimated at $105,408 per LY gained; in a fully incremental analysis, all other regimens were dominated (higher costs and lower LYs or a higher ICER). Conclusion. Olara + Dox is cost-effective for STS treatment compared with Dox and other standard-of-care regimens at willingness-to-pay thresholds of $150,000 per LY and above.

scholarly journals Trends in the incidence of soft tissue sarcomas in the United States from 1973 through 1987

Cancer ◽  
1993 ◽  
Vol 72 (2) ◽  
pp. 486-490 ◽  
Author(s):  
Julie A. Ross ◽  
Richard K. Severson ◽  
Scott Davis ◽  
John J. Brooks
Keyword(s):  
United States ◽  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
The United States

Radiotherapy Remains Underutilized in the Treatment of Soft-Tissue Sarcomas: Disparities in Practice Patterns in the United States

2020 ◽  
Vol 108 (2) ◽  
pp. E59-E60
Author(s):  
Jacob Shabason ◽  
Vishruth Reddy ◽  
Varsha Jain ◽  
Sriram Venigalla ◽  
William Levin ◽  
...  
Keyword(s):  
United States ◽  
Soft Tissue ◽  
Practice Patterns ◽  
Soft Tissue Sarcomas ◽  
The United States

scholarly journals Incidence, Treatment and Outcome of Patients with Retroperitoneal Soft-Tissue Sarcoma in Switzerland 2005–2015: A Population-Based Analysis

2021 ◽  
Author(s):  
Johanna C. F. Willburger ◽  
Marco von Strauss ◽  
Caspar J. Peterson ◽  
Tracy R. Glass ◽  
Christoph Kettelhack
Keyword(s):  
Soft Tissue ◽  
Mortality Rate ◽  
Soft Tissue Sarcoma ◽  
Age Distribution ◽  
High Volume ◽  
Population Based ◽  
Primary Diagnosis ◽  
Clear Trend ◽  
Retroperitoneal Soft Tissue Sarcoma ◽  
Overall Mortality

Abstract Background Reports on the epidemiology and mortality of retroperitoneal soft tissue sarcoma (RSTS) in Switzerland are scarce. This study investigates the incidence and outcomes of surgically treated RSTS inpatients in Switzerland depending on the hospital type and size. Methods Data from the Swiss Federal Statistical Office were used to conduct a retrospective analysis of all RSTS inpatients and hospitalizations in Switzerland between 2005 and 2015. RSTS was identified by the code C48.x of the International Classification of Diseases (ICD-10). Sarcoma centers were identified by the annual total number of sarcoma patients (> 50 patients/year). The analysis of yearly incidence, age distribution as well as in-hospital complication and mortality was performed for non- and surgical-treated patients. A centralization of treating sarcoma patients was analyzed by the trend of hospitalizations in sarcoma centers and high-volume hospitals. Results During 2005–2015, 2.801 hospitalizations (1651 patients) were admitted to Swiss hospitals with the primary diagnosis of a RSTS. The yearly number of RSTS patients and the incidence (1.91/100.000) stayed constant within these 11 years. There were five sarcoma centers. We saw a clear trend of RSTS patients being treated (especially surgically) in centers over the 11 years. The complication rate of surgical-treated patients was higher in sarcoma centers (55% vs. 40%), though the overall mortality rate was lower (3.2% vs. 9.1%). Conclusion Centralization of RSTS treatment to certified sarcoma centers leads to a lower overall mortality rate and thus is highly recommended.

Sign in / Sign up

Export Citation Format

Share Document